Pharmaceutical News

RSS

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

AMRI announced today that it has received approval from the Italian Medicines Agency (AIFA) for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union (EU).

4 Feb 2011

MedAssurant, UNC to assess relationship between insulin and cancer development

MedAssurant, a leading provider of data-driven healthcare solutions, today announced the initiation of a joint study with the University of North Carolina to assess the relationship between the use of long-acting insulin to treat diabetes and the development of cancer.

4 Feb 2011

Sodium Thiosulfate Injections recalled

American Regent is conducting a nationwide voluntary recall.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

FDA approves Hospira's topotecan for SCLC

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Public health experts: Improved community engagement needed to prevent pandemic spread

In the current issue of Journal of Public Health Management and Practice, public health experts assert that improved community engagement is needed to prevent the spread of pandemics.

3 Feb 2011

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi's dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

New study highlights black box warning inconsistencies on drug's label

A new study highlights inconsistencies in black box warnings - medication-related safety warnings on a drug's label - and argues for a more transparent and systematic approach to ensure these warnings are consistent across all drugs within a same category, and any additions to warnings, on the back of a drug withdrawal for example, are done within a reasonable and uniform time period.

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Chronic inflammation has been directly associated with heart disease and other physical ailments. But LSU graduate student Nathanial Gilbert and Professor of Biological Sciences Marcia Newcomer, together with Associate Professor Sue Bartlett, have developed the first 3-D model of Human 5-Lipoxygenase, or 5-LOX, the molecule responsible for creating inflammatory compounds that provoke asthma.

3 Feb 2011

Malarial drugs may help treat specific form of frontotemporal dementia

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain, which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin.

3 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Pharmaceutical News

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

MedAssurant, UNC to assess relationship between insulin and cancer development

Sodium Thiosulfate Injections recalled

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

FDA approves Hospira's topotecan for SCLC

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Public health experts: Improved community engagement needed to prevent pandemic spread

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Losartan improves effectiveness of nanotherapeutics against cancer

New study highlights black box warning inconsistencies on drug's label

FDA disallows obesity drug Contrave pending further large-scale testing

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

LSU biochemists develop 5-LOX 3-D model to design effective asthma medication

Malarial drugs may help treat specific form of frontotemporal dementia

Researchers discover potential vaccine capable of reducing H. pylori colonization

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

New research: Antioxidants in pecans may prevent development of various diseases

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Latest News